Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Study Overview: Mirum Pharmaceuticals is conducting a Phase 2 ...

An international research team, led by Shinghua Ding at the University of Missouri, has identified a previously unknown ...

Thirteen-year-old Leo Barker’s father, Tom, upended his research to stall a rare genetic illness that strikes 1 in 50,000 ...

Hayden Eastbury from Newcastle, NSW, has embarked on an Australia-wide trip to visit every ABC bureau across the country. The 17-year-old lives with the genetic condition fragile X syndrome. His ...

Shares of Harmony Biosciences Holdings, Inc. HRMY lost 16.56% on Sept. 24 after the company announced the failure of the late-stage registrational RECONNECT study on pipeline candidate ZYN002 in ...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ...

PLYMOUTH MEETING - Harmony Biosciences Holdings, Inc. (Nasdaq:HRMY), a profitable pharmaceutical company with annual revenues of $772 million, announced Wednesday that its Phase 3 clinical trial of ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). The ...

PLYMOUTH MEETING, Pa., September 24, 2025--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the ...

Tumor lysis syndrome has evolved and become less predictable with the introduction of new cancer therapies. This review explores risk factors and causes of the syndrome, as well as strategies for ...